AVADEL PHARMACEUTICALS PLC
SPONSORED ADR · CUSIP 05337M104
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $16.00.
Trends to Q1 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 77 |
| Q4 2022 | 83 |
| Q1 2023 | 93 |
| Q2 2023 | 102 |
| Q3 2023 | 100 |
| Q4 2023 | 115 |
| Q1 2024 | 120 |
| Q2 2024 | 10 |
| Q3 2024 | 5 |
| Q4 2024 | 3 |
| Q1 2025 | 3 |
| Q2 2025 | 3 |
| Q3 2025 | 3 |
| Q4 2025 | 2 |
| Q1 2026 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q2 2024 | 3 | 112 |
| Q3 2024 | 0 | 6 |
| Q4 2024 | 0 | 2 |
| Q1 2025 | 1 | 0 |
| Q2 2025 | 0 | 0 |
| Q3 2025 | 0 | 0 |
| Q4 2025 | 0 | 1 |
| Q1 2026 | 0 | 1 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q2 2025 | $215.5k | $0 | 0.00 |
| Q3 2025 | $0 | $0 | — |
| Q4 2025 | $0 | $0 | — |
| Q1 2026 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| Knoll Capital Management, LLC | Sold out | -600.0k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
No one currently above 5% in the filings since 19 Dec 2024.
Fell to 5% or below in the last year: GENDELL JEFFREY L (4.9%, 2026-02-06)
Holders, Q1 2026
| Manager | Shares | Change |
|---|---|---|
| HUNTINGTON NATIONAL BANK 0.00% of their portfolio | 1 $16 | Unchanged |